Sphinogosine-1-phosphate receptor modulators for treatment of cardiopulmonary disorders

A compound of claim 1 of formula (IC)

• wherein Ar1 is aryl, Ar2 and Ar3 are independently selected heteroaryl;
• wherein any aryl or heteroaryl ring system of Ar1, Ar2, or Ar3 is optionally fused with a cycloalkyl or a heterocyclyl ring;
• wherein any aryl or heteroaryl of Ar1, Ar2, or Ar3 is each optionally independently mono- or multi-substituted with up to three substituents selected from the group consisting of (C1-C4)alkyl, (C2-C4)alkenyl, halo, halo(C1-C4)alkyl, OH, monohydroxy(C1-C4)alkyl, dihydroxy(C2-C4)alkyl, monohydroxy(C1-C4)alkoxy, dihydroxy(C2-C4)alkoxy, (C1-C4)alkoxy, (C2-C6)acyl, (C1-C6)alkoxycarbonyl(CH2)0-2, carboxy(CH2)0-2, oxo, cyano, NR2(CH2)0-2, NR2C(═O)(CH2)0-2, NR2C(═O)(CH2)0-2O(CH2)0-2, (C1-C4)C(═O)N(R), (C1-C4)OC(═O)N(R), C═NOR, (C3-C10)cycloalkyl, (5- to 10-membered)heterocyclyl, (C6-C10)aryl, and (5- to 10-membered) heteroaryl;
• wherein any cycloalkyl, heterocyclyl, aryl or heteroaryl substituent of Ar1, Ar2, or Ar3 is itself optionally substituted with up to three secondary substituents selected from the group consisting of (C1-C4)alkyl, (C2-C4)alkenyl, halo, halo(C1-C4)alkyl, OH, monohydroxy(C1-C4)alkyl, dihydroxy(C2-C4)alkyl, monohydroxy(C1-C4)alkoxy, dihydroxy(C2-C4)alkoxy, (C1-C4)alkoxy, (C2-C6)acyl, (C1-C6)alkoxycarbonyl(CH2)0-2, carboxy(CH2)0-2, oxo, cyano, NR2(CH2)0-2, NR2C(═O)(CH2)0-2, NR2C(═O)(CH2)0-2O(CH2)0-2, (C1-C4)C(═O)N(R), (C1-C4)OC(═O)N(R), and C═NOR;
• each R is independently H, (C1-C4)alkyl, hydroxy(C2-C4)alkyl, cyano, or ((C1-C4)alkyl-O)1-2(C1-C4)alkyl, or two R groups together with an atom to which they are both joined can form a ring;
• each R′ is independently H, (C1-C4)alkyl, hydroxy(C2-C4)alkyl, (CH2)0-2C(═O)O(C1-C4)alkyl, or (C3-C6)cycloalkyl;
• X is a bond, (CH2)1-2, (CH2)0-2N(R)(CH2)0-2, (CH2)0-2O(CH2)0-2, (CH2)0-2N(R)C(═O)(CH2)0-2, (CH2)0-2C(═O)N(R)(CH2)0-2, (CH2)0-2N(R)C(═O)O(CH2)0-2, or (CH2)0-2OC(═O)N(R)(CH2)0-2;
• L is a bond, NR, C(═O), SO2, C(═NR), C(═O)CR2, C(═O)CH(N(R)C(═O)(C1-C4)alkyl, C(═O)CH(N(R)C(═O)O(C1-C4)alkyl, C(═O)CH(NR2), C(═O)CR(halo), or is
• wherein wavy lines indicate points of bonding,
• or a pharmaceutically acceptable salt thereof.